Surgical Techniques and Risk of Postoperative Recurrence in CD: A Game Changer?

Gaetano Luglio\textsuperscript{a} Toru Kono\textsuperscript{b}

\textsuperscript{a}Department of Medical and Surgical Gastrointestinal Diseases, Endoscopic Surgery Unit, School of Medicine, University of Naples Federico II, Naples, Italy; \textsuperscript{b}Advanced Surgery Center, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan

\begin{abstract}
\textbf{Background:} Since its first description, the role of surgery in Crohn’s disease (CD) has always been controversial; in fact, it has been mainly considered as a gastroenterological disease for long time. Nevertheless, despite great advances in medical therapy, up to 70–80% of patients with CD will require surgery in their lifetime and up to 30% of them will undergo repeated surgeries due to recurrences. For these reasons, the idea of surgery as a tool in the therapeutic armamentarium to consider even in the early stage of the disease has progressively spread in the last decades, even corroborated by reports showing how primary surgery is able to definitively treat around half of the patients at long-term follow-up. More surgeons are nowadays more and more involved in developing techniques to reduce recurrences that have always been considered as part of the natural history of the disease so far. \textbf{Summary:} In this review, we will go through the role of surgery in the management of CD, showing the potential benefits of an early surgical approach as well as the impact of surgical research in the natural history of the disease. From this standpoint, we will show the role of different anastomotic configurations, emphasizing how more and more data are definitively establishing the impact of the novel Kono-S anastomosis in reducing endoscopic and surgical recurrence. Mesentery-based surgery is a novel and appealing surgical perspective, but more data are required. \textbf{Key Messages:} Surgery has demonstrated to be a crucial tool in the therapeutic armamentarium for the management of CD. Early surgery and novel surgical techniques, such as the Kono-S anastomosis, may have an impact on the natural history of the disease, including the possibility to prevent recurrences.
\end{abstract}

\begin{correspondence}
Correspondence to:
Gaetano Luglio, gaetano.luglio@unina.it
\end{correspondence}
rical resection of the involved intestinal tract was considered as the only therapeutic viable road. Nevertheless, the surgeon who performed those procedures was not included in the authorship list (Dr. A.A. Berg, Mount Sinai Hospital, New York, NY, USA), and the disease was named by Dr. B. B. Crohn, an eminent internist. Doing a time flight of about 90 years, the role of surgery still seems muted as recommended in an authoritative review published by Torres et al. [2] in The Lancet. In fact, the authors proposed a therapeutic algorithm in which the word “surgery” was not contemplated while in the text they dedicated only a quarter of a page to surgical indications, limited to medical therapy failure and obstructive phenotype of the disease. Willing to make a comparison, surgery could be seen as a “Cinderella” in CD fairy tale.

Even though it is unquestionable that surgery rates decreased during the last 2 decades, a meta-analysis showed that the risk of surgery at 1, 5, and 10 years after diagnosis of CD was 16.3, 33.3, and 46.6%, respectively, and up to 48% of these patients will be in need of multiple surgeries due to recurrences, despite modern biological therapies and medical optimization [3–5]. Furthermore, an endoscopic/sonographic-based risk matrix model to predict 1-year risk of surgery for severe/refractory CD patients has been recently developed [6]. According to Rispo et al. [6], Simple Endoscopic Score for Crohn’s Disease (SES-CD) ≥9, bowel wall thickening ≥7 mm, small bowel CD extension at bowel sonography ≥33 cm, and strictureting/penetrating behavior were the only independent factors predictive of surgery at 1 year.

Bearing this in mind, the question spontaneously arises: What can surgeons do to have an impact on the natural history of CD? In other words, is it time for Cinderella to become a princess?

Surgery-First Approach

In order to support a “surgery-first approach,” long-term studies demonstrated that there is a 50% chance of not requiring any further operation for CD after primary ileocolic resection [7, 8]. The idea of an early surgery has been debated for a long time: the issue is whether to consider surgery to be the “last resort” when any other medical options have failed, a part of a multimodal strategy, or even an alternative to long-term medical therapy [9–11]. Considering that surgery for primary disease is technically easier and has lower complication rates compared with surgery for recurrent disease and after immunosuppressant therapy, this latter possibility is even more captivating. The main problem in implementing early surgery in clinical practice has been the lack of prospective and randomized data. From this standpoint, results from the LIRIC trial provided crucial insights [12]. This study demonstrated that laparoscopic ileocolic resection is a safe alternative to infliximab in case of localized (<40 cm) inflammatory terminal ileitis after the failure of conventional therapy. Patients who were nonresponsive to corticosteroids, thiopurines, or methotrexate were enrolled in this randomized, controlled, multicenter, open-label trial. The primary outcome was 1-year quality of life based on the evaluation of the Inflammatory Bowel Disease Questionnaire (IBDQ), 12 months after treatment. Secondary outcomes took into account items like general quality of life, assessed with the Short Form-36 (SF-36), including its physical and mental domains, days of inability to participate in social life, and esthetic results. In the LIRIC study, laparoscopic ileocolic resection, although not superior, appeared to be similar to infliximab treatment in terms of restoring the quality of life (mean IBDQ: 178 vs. 172 at 12 months) and not associated with significantly increased morbidity. More, long-term follow-up reveals that more than one-third of patients in the infliximab group will require surgery anyway after 70 weeks, whereas only a quarter of patients who received resection will need anti-TNF medical therapy within 112 weeks. Recently, retrospective long-term follow-up results of this trial were published [13]; in detail, data were collected from 134 (94%) of 143 patients previously included in the trial, of whom 69 underwent resection and 65 received infliximab. After a median follow-up of 63.5 months, 18 (26%) patients belonging to the resection group started anti-TNF therapy and no one required a second resection. Twenty-nine patients in the resection group did not receive any additional CD-related medication, although 14 (48%) of these patients were given prophylactic immunomodulator therapy. On the other hand, 31 (48%) patients of the infliximab group had a CD-related resection, and the remaining 34 patients maintained, switched, or escalated their anti-TNF therapy.

Conventional Anastomosis

In the last decade, a common challenge has been to define whether any role is played by the anastomotic configuration to reduce recurrences for CD. To date, there is still a lack of clear consensus regarding the best anastomotic technique after ileocolic resection for CD; in fact, no anastomotic technique has previously demonstrated a clear advantage in terms of preventing recurrences [14].

With the assumption that stapled side-to-side anastomosis may create physiological alteration of the intestinal function from transection of the circular muscular layer
and antiperistaltic configuration (independently from CD recurrence), Gajendran et al. [15] ran a single-center prospective observational study in which 128 CD patients undergoing surgical resection were enrolled, comparing side-to-side and end-to-end anastomoses. Primary outcomes evaluated 2-year postoperative healthcare utilization (measured by proportion of patients who had emergency department visit, hospitalization, abdominal imaging, and repeat bowel resection due to CD-related reasons) and quality of life. Results highlighted that side-to-side patients showed higher rates of emergency department visits (33.3 vs. 14.7%; \( p = 0.01 \)), hospitalizations (30 vs. 11.8%; \( p = 0.01 \)), and abdominal computed tomography scans (50 vs. 13.2%; \( p < 0.001 \)) with lower QoL (mean short inflammatory bowel disease questionnaire 47.9 vs. 53.4; \( p = 0.007 \)). Moreover, there was no difference among the 2 groups in the 30-day surgical complications and 2-year patterns of disease activity, CD medication requirement, endoscopic recurrence, and need for new surgical management (all \( p > 0.05 \)) [15]. An additional concern regarding the stapled side-to-side anastomosis comes from some endoscopists that emphasize how this anastomosis can be sometimes difficult to scope, because of a kind of U-turn shape that is created between the colon and the ileum, other than for the "pouch-like" configuration of the anastomosis itself.

By contrast, ECCO/ESCP consensus on Surgery for Crohn’s Disease is in favor of a wide lumen stapled side-to-side (functional end-to-end) anastomosis, and 3 meta-analyses support this statement [16]. In the first one by Simillis et al. [17], 661 patients were included, and the anastomotic leak rate resulted higher for the end-to-end anastomosis versus side-to-side anastomosis (OR 4.37; \( p = 0.02 \)). Moreover, overall postoperative complications (OR 2.64; \( p < 0.001 \)) and length of hospital stay were accordingly higher (by 2.81 days; \( p = 0.007 \)) when an end-to-end anastomosis was performed. A later meta-analysis by Guo et al. [18] confirmed the superiority of a side-to-side anastomosis over other configurations in terms of overall postoperative complications (OR 0.6; \( p = 0.01 \)) but failing to demonstrate statistically significant differences regarding leak rate, endoscopic and clinical recurrence, and reoperation for recurrence. A further meta-analysis by He et al. [19] compared 396 stapled side-to-side with 425 handsewn end-to-end anastomoses. Stapled side-to-side fashion was superior in all endpoints: overall postoperative complications (OR 0.54, 95% CI: 0.32–0.93), anastomotic leak (OR 0.45, 95% CI: 0.20–1.00), recurrence (OR 0.20, 95% CI: 0.07–0.55), and reoperation for recurrence (OR 0.18, 95% CI: 0.07–0.45). Finally, a network meta-analysis of 11 trials and 1,113 patients confirmed the superiority of stapled side-to-side anastomosis in terms of overall complications, clinical recurrence, and reoperation for recurrence. Leak rate, surgical site infections, mortality, and length of stay were not affected by the choice of the anastomosis technique [20]. After all, it must be highlighted that just a minority of patients were included in RCTs resulting in a low quality of the studies included in all meta-analyses.

As for other evidences, the choice of a stapled side-to-side anastomosis found moderate agreement in the 2015 Think Tank on CD surgery of the Italian Society of Colorectal Surgery (SICCR) (“Agree” 62.5%) [21]. Furthermore, a recent “position statements” by the same society supports again the use a wide lumen stapled side to side (functional end-to-end) as the preferred anastomotic technique to be fashioned after ileocolic resection, on the light of current evidence [22].

**Surgical Prophylaxis**

Even if it is true that the anastomosis is often the site of postoperative recurrence, it must be said that additional recurrence sites have been also described far from the anastomosis. Fichera et al. [23], for example, carried out a retrospective study on a prospective maintained database, reporting that around one-third of surgical recurrences involve bowel tracts far from the primary anastomosis: in detail, duodenum (1%), jejunum/ileum (34%), terminal ileum/neoterminal ileum (42%), and colon/rectum (23%).

Nevertheless, from a surgical perspective, the perpetual will to positively impact the clinical history of these patients, preventing recurrences at the anastomotic sites, opened the doors to the ideation of a novel type of anastomosis: the Kono-S anastomosis (Fig. 1). Kono-S anastomosis is defined as a handsewn antimesenteric functional end-to-end anastomosis. The mesentery of the intestinal segment to be excised is divided at the mesenteric edge of the bowel wall by the use of a vessel-sealing system to avoid an unnecessary devascularization and denervation of residual bowel and to maintain adequate blood supply and neural control to the anastomotic site. The intestine is transected by use of a linear stapler such that the mesenteric side was located in the center of the stump, at a 90° angle to the mesentery. Both ends of the stump were reinforced with 3/0 braided polyglycolide lactide (Vicryl). Before the anastomosis, the stumps were sutured by 4 or 5 stitches together to create a supporting column (Fig. 1a); hence, the name Kono-S, as in supporting, which would maintain orientation and
Longitudinal enterotomies of approximately 7–8 cm are then performed to achieve a transverse lumen on the antimesenteric side, 0.5–1 cm from the supporting column to maximize the supporting effect of the column on the anastomosis (Fig. 1a, b). The anastomosis is then created transversely in handsewn fashion with a single or two-layer 3/0 Vicryl running sutures, which thus result in a large anastomosis [24]. This results in a large anastomosis. Moreover, the supporting column is located immediately behind the posterior wall of the anastomosis (Fig. 1c), providing a rigid and stable support to prevent mechanical deformation and functional constriction of the lumen of the anastomosis like as a “back bone” of the anastomosis.

Results from Early Studies regarding This Novel Type of Anastomosis Are Encouraging

Kono et al. [25] performed Kono-S anastomosis in 69 CD patients from 2003 to 2009 and compared this group with a historical cohort of 73 CD patients who underwent conventional anastomosis from 1993 to 2003. It was found significantly lower endoscopic recurrence rates in the Kono group than in the conventional one, with a lower probability of anastomotic surgical recurrence in the Kono group after 5 years (0 vs. 15%; \( p < 0.0013 \)), and these results were independent from the use of biologics in the perioperative period. Therefore, no patient with the Kono-S anastomosis presented a surgical recurrence. The drawback of this first report lays in its not randomized retrospective design: moreover, the control group is an historical cohort. Similar results were then confirmed by a larger multicenter study in which 187 patients in Japan (144 patients, group J) and USA (43 patients, group US) who received the Kono-S anastomosis were included [26].

The 5-year surgical recurrence-free rate was 98.6%, and the 10-year surgical recurrence-free rate was also 98.6% in group J. In the US group, no surgical recurrence has occurred during the follow-up period of 32 months. The 5-year cumulative surgical recurrence rate was 1.8% (95% CI: 0–4.3%), and the 10-year cumulative surgical recurrence rate was also 1.8% (95% CI: 0–4.3%) in group J. The 5-year cumulative surgical recurrence rate was 1.7% (95% CI: 0–4.2%), and the 10-year cumulative surgical recurrence rate was also 1.7% (95% CI: 0–4.2%) in cumulative experience. Unfortunately, this study has some notable limitations too, again it is a nonrandomized retrospective study with a relatively small sample size and a shorter follow-up of the US group.

In their single-center retrospective nonrandomized study, Shimada et al. [27] compared the Kono-S anastomosis to the handsewn end-to-end anastomosis. With regard to long-term outcomes, Kaplan-Meier analysis showed a lower probability of a second surgery at the anastomosis site in the Kono group than in the end-to-end one. The 5-year surgery-free survival rate at the anastomosis site was significantly higher with the Kono-S anastomosis (95.0% [95% CI: 0.90–1.00]) than that with the end-to-end anastomosis (81.3% [95% CI: 0.73–0.89]).
Moreover, only 4 patients (3.4%) in the Kono group underwent a second surgery after a mean of 47.3 months (IQR, 31–66), while 24 (24.4%) patients in the end-to-end group underwent such a second surgery after a mean of 99 months (IQR, 64–115). More than 1 year after surgery, 21 patients developed surgical recurrence at the anastomosis site. During this period, the use of Kono-S anastomosis resulted as a protective factor from the risk of surgical recurrence (OR, 0.08; 95%CI: 0.02–0.33; \( p < 0.001 \)) [27]. As for the previous ones, the design of this study is its main limitation, in addition to the absence of endoscopic recurrence evaluation; the leak rate in the standard group (17.3 vs. 5.1%) seems to be higher compared to data usually reported from the literature and might be a further aspect that biased results.

Aiming to overcome these limitations, the Supreme-CD study [28] was designed. A total of 79 CD patients were randomized in the “Kono-S group” (36 patients) and in the “conventional group” (43 patients); in this latter group, patients received the conventional side-to-side antiperistaltic anastomosis (functional end-to-end). After 6 months, 22.2% in the Kono group and 62.8% in the conventional group presented an endoscopic recurrence (OR, 0.08; 95%CI: 0.02–0.33; \( p < 0.001 \)) [27]. As for the previous ones, the design of this study is its main limitation, in addition to the absence of endoscopic recurrence evaluation; the leak rate in the standard group (17.3 vs. 5.1%) seems to be higher compared to data usually reported from the literature and might be a further aspect that biased results.

The surgical technique itself and configuration of the Kono-S anastomosis could pathophysiologically explain these results: the supporting column preserves the feature and diameter of the anastomosis, in order to avoid distortions and strictures associated with recurrent diseases at the anastomotic site, especially on the mesenteric side which is identified as the original site of anastomotic CD recurrence. Further benefits of this innovative surgical technique include the preservation of blood stream and

| Table 1. Current evidence on Kono-S anastomosis |
|-----------------------------------------------|
| Authors          | Year | Countries     | Study design | Patients, \( n \) | Brief Kono-S results                                      |
|------------------|------|---------------|--------------|------------------|----------------------------------------------------------|
| Kono et al. [25] | 2011 | Japan         | Comparative with historical cohort | 142 (69 Kono-S) | Median Rutgeerts score in Kono-S group: 2.6 Median Rutgeerts score in control group: 3.4 |
| Kono et al. [29] | 2016 | Japan, USA    | Case series  | 187              | Group J: 2 surgical anastomotic recurrences (median follow-up of 65 months) Group US: 0 surgical anastomotic recurrences (median follow-up of 32 months) |
| Shimada et al. [27] | 2018 | Japan         | Comparative with historical cohort | 215 (117 Kono-S) | Surgical recurrence in 4 patients (3.4%) in the Kono-S group and 24 (24.4%) in the end-to-end group |
| Seyfried et al. [30] | 2019 | Germany       | Case series  | 53               | No anastomotic recurrence was detected |
| Luglio et al. [28] | 2020 | Italy         | RCT          | 79 (36 Kono-S)   | Overall postoperative recurrence in Kono group versus side-to-side group: 22.2 versus 62.8% Severe postoperative endoscopic recurrence in Kono group versus side-to-side group: 13.8 versus 34.8% |
| Katsuno et al. [31] | 2015 | Japan         | Case series  | 30               | Mean Rutgeerts score: 0.7 (0–3) Median follow-up: 14.8 months (3 –37) (for 19 patients) |
| Krane et al. [32] | 2015 | USA           | Case series  | 96               | Mean Rutgeerts score: 0.71 (0–3) Mean follow-up: 22.8 months (3.0–53.9) (for 62 patients) |
| Fichera et al. [33] | 2012 | Japan, Italy  | Case series  | 44               | Mean Rutgeerts score: 0.72 (0–3) Mean follow-up: 6.8 months (for 18 patients) |

Preventing Surgical Recurrences in Crohn’s Disease

Inflamm Intest Dis 2022;7:21–27
DOI: 10.1159/000515372
innervation, both factors associated with high risk of anastomotic recurrence in CD [34]. A larger multicenter randomized trial (NCT03256240) is currently ongoing, recruiting patients from USA and Europe, which will hopefully give an end to the story, fully establishing the role of the Kono-S anastomosis in impacting the natural history of CD.

With regard to the role of surgery in influencing the natural history of CD, a “mesentery-based” surgery is gaining appraisal [35]. A recent study by Coffey et al. [36] demonstrated, for the first time, that the inclusion of the mesentery as part of intestinal resection is associated with reduced surgical recurrence. The authors compared surgical recurrence in 2 cohorts: in cohort A (30 patients), a standard ileocecal resection was performed, cutting the mesentery close to the bowel wall; in cohort B (34 patients), the mesentery supplying the ileocecal affected segment was fully mobilized and resected together with the bowel. The cumulative reoperation rate in cohort A was 40%, while it was only 2.9% in cohort B. Most of the recurrences happened within 2 years after surgery. Mesentry-sparing resection was, therefore, recognized as an independent risk factor for surgical recurrence. Coffey et al. [36] also developed a novel “mesenteric disease activity index” based on the presence of “fat wrapping” and “mesenteric thickening”: other than being related to the Crohn’s Disease Activity Index (CDAI) and to the percentage of circulating fibrocytes, it was also found to predict surgical recurrence. Despite the great interest of Coffey’s idea, the absence of randomized data and clear biases in the study design certainly advocate the need of prospective and well-designed studies to definitively assess the role of the mesentery in preventing recurrences in CD.

Conclusions

Even though novel clinical trials are certainly necessary to fully address current hot topics and unmet needs in CD treatment, all these data make us feel ready to answer the provocative question we have raised in the beginning: yes, it is time for Cinderella to become a princess.

Conflict of Interest Statement

The authors declare no conflicts of interest regarding this publication.

Author Contributions

Both the authors have contributed to the conception of the work, data collection and interpretation, drafting of the manuscript, critical revision, and final approval.

References

1. Crohn BB, Ginzburg I, Oppenheimer GD. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Bur- ril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA. 1984;251(1):73.
2. Torres J, Mehandru S, Colombel JF, Peyrin- Biroulet L. Crohn’s disease. Lancet. 2017; 389(10080):1741.
3. Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.
4. Frolkis AD, Lipton DS, Fiest KM, Negrón ME, Dykeman J, Debruyn J, et al. Cumulative incidence of second intestinal resection in Crohn’s disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109:1739–48.
5. Shinagawa T, Hata K, Ikeuchi H, Fukushima K, Futami K, Sugita A, et al. Rate of reopera- tion decreased significantly after year 2002 in patients with Crohn’s disease. Clin Gastroen- terol Hepatol. 2020.
6. Rispo A, Imperatore N, Testa A, Bucci L, Luglio G, De Palma GD, et al. Combined endos- copic/sonographic-based risk matrix model for predicting one-year risk of surgery: a prospective observational study of a tertiary cen- tre severe/refractory crohn’s disease cohort. J Crohns Colitis. 2018;12:784–93.
7. Weston LA, Roberts PL, Schoertz DJ Jr, Coller JA, Murray JJ, Rusin LC. Ileocelec resection for acute presentation of Crohn’s disease of the ileum. Dis Colon Rectum. 1996;39(8): 841–6.
8. Kim NK, Senagore AJ, Luchtefeld MA, MacK- eigan JM, Mazier WP, Belknap K, et al. Long- term outcome after ileocelec resection for Crohn’s disease. Am Surg. 1997;63(7):627–33.
9. Krause U. Early or late operation in the treat- ment of Crohn’s disease [Internet]. Scand J Gastroenterol. 1971;6(6):479–81 [cited 2018 Sept 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4399325.
10. Latella G, Caprilli R, Travis S. In favour of early surgery in Crohn’s disease: a hypothesis to be tested [Internet]. J Crohns Colitis. 2011 Feb;5(1):1–4 [cited 2018 Sept 12]. Available from:
11. Bemelman WA, Allez M. The surgical inter- vention: earlier or never? [Internet]. Best Pract Res Clin Gastroenterol. 2014 Jun;28(3): 497–503 [cited 2018 Sept 12]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1521691814000572.
12. Ponsioen CY, de Groof EJ, Eshuis EJ, Garden- broek TJ, Bossuyt PPM, Hart A, et al. Laparoscopic ileoceleal resection versus inflix- imab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicen- tre trial. Lancet Gastroenterol Hepatol. 2017.
Preventing Surgical Recurrences in Crohn’s Disease

13 Stevens TW, Haasnoot ML, D’Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIRIC trial. *Lancet Gastroenterol Hepatol*. 2020;5:900–7.

14 SICCR Current Status of Crohn’s Disease Surgery Collaborative. National variations in perioperative assessment and surgical management of Crohn’s disease: a multicentre study. *Colorectal Dis*. 2020;23:94–104.

15 Gajendran M, Bauer AJ, Buchholz BM, Waton AR, Koutroubakis IE, Hashash JG, et al. Ileocecal anastomosis type significantly influences long-term functional status, quality of life, and healthcare utilization in postoperative Crohn’s disease patients independent of inflammation recurrence. *Am J Gastroenterol*. 2018;113:576–83.

16 Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, et al. ECCO-ESCP consensus on surgery for Crohn’s disease. *J Crohns Colitis*. 2018;12:1–16.

17 Simillis C, Purkayastha S, Yamamoto T, Strong SA, Darzi AW, Tekkis PP. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn’s disease. *Dis Colon Rectum*. 2007;50(10):1674–87.

18 Guo Z, Li Y, Zha W, Gong J, Li N, Li J. Comparing outcomes between side-to-side anastomosis and other anastomotic configurations after intestinal resection for Crohn’s disease: a meta-analysis. *World J Surg*. 2013.

19 He X, Chen Z, Huang J, Lian L, Rouniyar S, Wu X, et al. Stapled side-to-side anastomosis might be better than handsewn end-to-end anastomosis in ileocolic resection for Crohn’s disease: a meta-analysis. *Dig Dis Sci*. 2014;59(7):1544–51.

20 Feng J-S, Li J-Y, Yang Z, Chen X-Y, Mo J-J, Li S-H. Stapled side-to-side anastomosis might be benefit in intestinal resection for Crohn’s disease: a systematic review and network meta-analysis. *Medicine*. 2018;97:e0315.

21 Pellino G, Selvaggi F, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian society of colorectal surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: Crohn’s disease. *Tech Coloproctol*. 2015;19:639–51.

22 Pellino G, Keller DS, Sampietro GM, Angri man I, Carvello M, Celentano V, et al. Inflamm atory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn’s disease. *Tech Coloproctol*. 2020;24:397–419.

23 Fichera A, Lovadina S, Rubin M, Cimino F, Hurst RD, Michelassi F. Patterns and operative treatment of recurrent Crohn’s disease: a prospective longitudinal study. *Surgery*. 2006;140:649–54.

24 Luglio G, Tropeano FP, Amendola A, Rispo A, Castiglione F,ucci L, et al. Preventing recurrence in Crohn’s disease: the Kono-S anastomosis with two-layer technique. *Tech Coloproctol*. 2020;24(11):1213–4.

25 Kono T, Ashida T, Ebisawa Y, Chisato N, Okamoto K, Katsuno H, et al. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn’s disease. *Dis Colon Rectum*. 2011;54:586–92.

26 Kono T, Fichera A, Maeda K, Sakai Y, Ohge H, Krane M, et al. Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn’s disease: an international multicenter study. *J Gastrointest Surg*. 2016;20:783–90.

27 Shimada N, Ohge H, Kono T, Sugitanri A, Yano R, Watadani Y, et al. Surgical recurrence at anastomotic site after bowel resection in Crohn’s disease: comparison of Kono-S and end-to-end anastomosis. *J Gastrointest Surg*. 2019.

28 Luglio G, Rispo A, Imperatore N, Giglio MC, Amendola A, Tropeano FP, et al. Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: the Su PREMe-CD study: a randomized clinical trial. *Ann Surg*. 2020;272:210–7.

29 Kono T, Fichera A, Maeda K, Sakai Y, Ohge H, Krane M, et al. Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn’s disease: an international multicenter study. *J Gastrointest Surg*. 2016;20(4):783–90.

30 Seyfried S, Post S, Kienle P, Galata C. Die Kono-S-Anastomose in der Chirurgie des Morbus Crohn. *Der Chir*. 2019.

31 Katsuno H, Maeda K, Hanai T, Masumori K, Koide Y, Kono T. Novel antimetastatic functional end-to-end handsewn (kono-s) anastomoses for Crohn’s disease: a report of surgical procedure and short-term outcomes. *Dig Surg*. 2015;32:39–44.

32 Krane MK, Cannon LM, Allai ME, Kono T, Fichera A. A new antimetastatic functional end-to-end handsewn (Kono-S) anastomosis: feasibility and short-term outcomes in Crohn’s disease. *J Am Coll Surg*. 2015.

33 Fichera A, Zoccali M, Kono T. Antimetastatic functional end-to-end handsewn (Kono-S) anastomosis. *J Gastrointest Surg*. 2012;16(7):1412–6.

34 Peltrini R, Greco PA, Manfreda A, Luglio G,ucci L. Kono-S Anastomosis after intestinal resection for Crohn’s disease. *Updates Surg*. 2020;72:335–40.

35 Peltrini R,ucci L. "Mesentery-based surgery" to prevent surgical recurrence in Crohn’s disease: from basics to surgical practice. *Int J Colorectal Dis*. 2019;34:353–4.

36 Coffey CJ, Kiernan MG, Sahebally SM, Jarrar A, Burke JP, Kiely PA, et al. Inclusion of the mesentery in ileocolic resection for Crohn’s disease is associated with reduced surgical recurrence. *J Crohns Colitis*. 2018;12:1139–50.